Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

1.980 -0.080 (-3.88%)
Streaming Delayed Price Updated: 10:45 AM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach ↗
Why Are Gamma-Delta T Cells Important In Fighting Cancer? 
Via Benzinga
News headline image
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Recap: Century Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Analyst Ratings for Century Therapeutics ↗
 
Via Benzinga
News headline image
Century Therapeutics's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Where Century Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗
 
Via Benzinga
News headline image
Workday To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday ↗
Truist Securities raised the price target for Church & Dwight Co., Inc. (NYSE: CHD) from $95 to $105. Truist Securities analyst Bill Chappell upgraded the stock from Hold to Buy. Church & Dwight shares... 
Via Benzinga
News headline image
These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results ↗
Century Therapeutics, Inc. (NASDAQ: IPSC) reported weaker-than-expected second-quarter results. 
Via Benzinga
News headline image
Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Leadership Changes
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the AACR Annual Meeting 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Upcoming Investor Conferences
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Upcoming Investor Conferences
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate. 
Via MarketBeat
Topics Workforce
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 29 stocks made new 52-week lows. 
Via Benzinga
News headline image
5 Health Care Stocks That Are Diving - And May Rally ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 13 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Surge ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC ↗
Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.